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Calcium and vitamin D supplementation effects on 
metabolic factors, menstrual cycles and follicular responses 
in women with polycystic ovary syndrome: A systematic 
review and meta-analysis 
 
Abstract 
Background: Polycystic ovary syndrome (PCOS) is the most popular endocrine disorder 
in reproductive age with unknown etiology and many comorbidities. This systematic 
review focused on the effectiveness of calcium and vitamin D (Ca/ Vit.D) supplementation 
on metabolic factors, menstrual cycles, and follicular responses in PCOS patients.  
Methods: Relevant studies were identified from the following electronic databases 
including Pub Med, Web of Science, Cochrane Central Register of Controlled Trials 
(CENTRAL), The Cochrane Library, issue Oct. 2018, Evidence Based Medicine Reviews 
(EBMR), Google Scholar, EMBASE, as well as Farsi databases including Magiran and 
SID from 2000 to 2018. Out of 449 articles, six clinical trials met the inclusion criteria. 
Results: Out of six studies included in the study, only three studies had sufficient data for 
meta-analysis. Overall, studies showed that prescribing Ca/ Vit. D supplementation with 
metformin improved menstrual regularity and follicular maturation and significant 
decreases in serum insulin levels, homeostasis model of assessment-insulin resistance 
(HOMA-IR) and fasting blood sugar (FBS) and also significant rises on quantitative 
insulin sensitivity check index (QUICKI) at two studies. Hirsutism and level of 
testosterone decreased significantly after adding Ca/ Vit. D to metformin in two different 
studies. Based on two different trials, co-supplementation of Ca/ Vit. D had a significant 
impact to decrease serum triglycerides and VLDL-cholesterol levels as well as levels of 
cholesterol and LDL. 
Conclusion: It is possible that calcium and vitamin D supplementation improve menstrual 
disturbances and metabolic factors in PCOS in a long-term period, but further trials are 
still needed to confirm these findings. 
Keywords: Calcium and vitamin D, Polycystic ovary syndrome, Metabolic factors, 
Manstrual cycle. 
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Polycystic ovary syndrome (PCOS) is one of the most heterogeneous endocrine 
disorders in reproductive age affecting approximately 5-10% of females. PCOS is a 
chemical or clinical hyperandrogenism associated with chronic anovulation and polycystic 
ovary. The clinical features of PCOS include infertility, hyperandrogenism, obesity, 
abnormal glucose metabolism, insulin resistance (IR), hirsutism and acne vulgarism (1). 
PCOS prevalence in Iran was reported according to NIH and Rotterdam criteria 6/8% and 
19/5%, respectively, in 2014 (2). The causes of PCOS are unknown.  
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It is hypothesized that insulin resistance leads to 
hyperinsulinemia and as a result , increased insulin promotes 
secretion of androgens from the ovaries, which itself 
decreases the amount of serum sex hormone binding 
globulin (SHBG), therefore, serum free testosterone is 
elevated and ovarian follicle growth and maturation is 
altered by hyperinsulinemia and androgen excess (3). 
Women with PCOS may be at elevated risk of vitamin D 
deficiency (VDD). VDD has been observed in approximately 
67-85 percent of women with PCOS (4). Positive associations of 
VDD with some well- known co morbidities of PCOS including 
typ2 diabetes, insulin resistance, metabolic syndrome and 
cardiovascular disease has been reported (5, 6).  
Direct effect of calcium and vitamin D on the ovarian 
and/or adrenal steroid genesis pathway may be justified by 
the observed reduction in circulating androgens (7). Some 
studies reported positive correlations between total serum 
calcium with insulin level and insulin resistance and fasting 
serum glucose in the larger healthy population. 1,25 (OH) 
2D likely has effect on insulin secretion by the significant 
rise in intracellular ionic calcium level following 
1,25(OH)2D-stimulated secretion of insulin by islet cells (8). 
A significant decrease level of vitamin D; has been reported 
also, glucose and phosphorus level in overweight obese 
women with PCOS correlated negatively with insulin and 
insulin resistance and positively with vitamin D level (8). 
In accordance with limited evidence, calcium and 
vitamin D metabolism affects oocyte maturation and 
production of androgens (9). In Razavi’s study (2016), 
prescribing vitamin D-K-calcium co-supplementation for 8 
weeks among vitamin D-deficient women with PCOS has 
beneficial effects on serum dehydroepiandrosterone sulfate 
(DHEAS), free testosterone, plasma total antioxidant capacity 
(TAC), and malondialdehyde (MDA) concentrations (MDA) 
levels (10).  
Ott et al. (2012) found that parathyroid hormone (PTH) 
reversely correlated with serum calcium and 25OHD3, 
whereas positive correlations were found between PTH and 
body mass index as well as testosterone (11). Foroozanfard 
(2015) showed beneficial effects of calcium plus vitamin D 
co-supplementation for 8 weeks among overweight and 
vitamin D-deficient women with PCOS on inflammatory 
factors and biomarkers of oxidative stress (12). Some 
evidence has shown that vitamin D and calcium metabolism 
affects oocyte maturation and production of androgens but 
other studies have not agreed with these findings. There is a 
dearth of systematic review and meta-analysis on the effect 
of Ca/Vit D on menstrual cycles and metabolic factors in 
PCOS patients. No systematic review has also been 
conducted in this field in Iran. The main mechanism of Ca/ 
Vit. D effects have not yet been determined. Considering the 
lack of research and the validity of the results, this study 
reviews the current evidence and makes recommendations 
about the effect of calcium and vitamin D supplementation 
on metabolic factors, menstrual cycles and follicular 
responses in PCOS patients. 
 
 
Methods 
Literature Search strategy: Relevant studies were 
identified from the following electronic databases: Pub Med, 
Web of Science, Cochrane Central Register of Controlled 
Trials (CENTRAL), The Cochrane Library (issue 7, 2016), 
Evidence-Based Medicine Reviews (EBMR), Google 
scholar, EMBASE, Magiran and SID using keywords of 
polycystic ovarian syndrome, vitamin D, calcium 
compounds, calcitriol, and the combination of these 
keywords from 2000 to October 2018. Cited references of 
retrieved trials as well as systematic reviews were manually 
screened to identify any further relevant trials which was 
possibly missed in electronic search. Also, the authors were 
contacted for additional missing data. Out of 449 relevant 
published trials, six RCTs met the inclusion criteria and were 
reviewed systematically (figure 1) (13).  
Inclusion and exclusion Criteria: Studies were considered 
to be included in systematic review if they met all of the 
following criteria: 
Designed as randomized controlled trials (RCTs).  
Evaluated the impact of calcium plus vitamin D 
supplementation in PCOS patients. 
Measured outcomes include menstrual cycle regularity, 
follicular response and metabolic factors.  
Studies were excluded if they were short communications 
and case reports/ series as well as publications from 
meetings/conferences or studies which did not provide 
baseline descriptions of metabolic parameters. 
Data extraction: Two reviewers independently assessed and 
extracted the data using an arranged checklist. The extracted 
data included the first author, sample size, the age of 
subjects, diagnostic criteria for PCOS, criteria for exclusion, 
study design, intervention, the time period of intervention 
and the outcome measures (metabolic factors, regularity of 
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menses and follicular responses) (table 1). Disagreements between reviewers were resolved by consensus and arbitration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig1. Search strategy for systematic review.  
 
Table: 1 Characteristics of 6 clinical trials included in systematic review 
Key findings Intervention period 
and type of 
intervention 
Inclusion and exclusion 
criteria 
Sample  
size 
 
Age Year of 
data 
collection 
Author/ 
Reference/ 
Year of 
publication 
Regularity of Menes and 
pregnancy rate had no 
significant difference in three 
groups after treatment and  
Follicular response was not 
significant between 
prescribing Ca/ Vit. D or 
metformin alone, though 
relatively was higher in Group 
1 compared with Group 3(p = 
0.29). Frequency of response 
to treatment in Group 2 was 
higher than in the other two 
groups during the fifth and 
sixth months of the follow-up 
period. 
Intervention period: 3 
months 
Divided into three 
equal groups 
Group 1 received 
1,000 mg of calcium 
and 400 IU of vitamin 
D per day Orally. 
Group 2 received the 
same as Group 1, plus 
1,500 mg/day of 
metformin. 
Group 3 received 
1,500 mg/day of 
metformin. 
Inclusion: Rotterdam criteria1 
Exclusion: systemic diseases 
such 
as Cushing’s syndrome, 
hyperparathyroidism or 
hyperprolactinemia, 
androgen secreting tumors, 
history of 
abdominal/pelvic surgery, 
coexisting male factor 
infertility, 
or abnormal 
hysterosalpingography 
N=60 
sample in 
three 
group 
 
20-40 2004 
Tehran 
1- Batool 
Rashid  et al(13) 
2009 
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Prescribing Ca/ Vit. D in 
group3, compared with other 
groups, led to decreased 
serum insulin levels (P < 
0.03), HOMA-IR score (P 
<0.04) and a significant rise in 
QUICKI index )P < 0.001), 
significant decrease in serum 
triglycerides )P < 0.02) and 
VLDL-cholesterol levels (P 
<0.02), but had no significant 
effects on FPG, total LDL, 
HDL, and non-HDL-
cholesterol levels. Adjustment 
for age and baseline BMI did 
not affect findings except for 
HOMA-IR score (P<0.05). 
Intervention period : 
8 weeks 
four groups to 
receive: 
1) CALCIUM:1000 
mg/d calcium  
vitamin D placebo (n 
= 26); 
2) VITD:50,000 
IU/wk vitamin D  
calcium placebo (n = 
26) 
3) CA+vit D:1000 mg 
calcium/d   50,000
IU/wk vitamin D (n = 
26) 
4) placebo:calcium 
placebo  vitamin D 
placebo (n = 26) 
Inclusion: Rotterdam criteria 
Exclusion: aged<18 or >40 
years, those with BMI < 25 
kg/m2, individuals with 
neoplastic, hepatic, renal or 
cardiovascular disorders, 
malabsorptive disorders, 
those taking calcium and 
vitamin D within the last 6 
months and women who had 
calcium intake more than 
1500 mg per day using 
hormone therapy, 
antidiabetic, or anti-obesity 
medications within the last 6 
months intended to adopt a 
diet and/or a specific physical 
activity program 
N=104 
overweight 
and obese 
vitamin D 
deficient 
women 
18-40 2013 
kashan 
2- Zatollah 
Asemi(18) 
2014 
No Significant difference 
between groups before and 
after treatment in Cardio 
metabolic risk factor(FBS, 
LDL, cholesterol, systolic and 
diastolic blood pressure, 
BMI,TG. and just significant 
increased HDL in Ca/ Vit. D 
and metformin group and 
testosterone in metformin 
group. There was significant 
deference between groups 
after treatment in many 
factors such as BMI, BP, 
FBS, LDL, and Cholesterol 
(p<0.001). 
There was no statistically 
difference between rates of 
changes in the parameters 
under study in the patients 
with and without metabolic-
syndrome. 
Intervention period: 
12 weeks 
The selected 
individuals were 
divided in simple 
random form into 2 
groups 
First group: under 
treatment with 1000 
milligrams of 
Calcium and Vit-D-
400 IU twice a day. 
Plus metformin1500 
mg/day 
Second: : 
metformin1500 
mg/day 
Inclusion: Rotterdam criteria 
Exclusion: History of any 
underlying and chronic 
disease (chronic kidney 
disease, etc.), history of 
abdominal and pelvic surgery, 
abnormal 
hysterosalpingography, 
abnormal serum prolactin 
level, smoking, pregnancy, 
current or previous Statin use 
during the past 2 months, 
insulin use, use of 
corticosteroids, anti-obesity 
medication, and history of 
neoplastic diseases. 
N=72 20-45 2015 
Hamadan 
3Mohsen 
Gharakhani(17), 
-2015 
There was no statistically 
significant difference in 
folliclar size between groups 
(p=0.1) and the first and 
second month (p=0/82). 
Average size follicles in the 
first, second and third months 
was higher in intervention 
group compared with The 
control group (p<0/05) and 
size of follicles in the third 
compared with the second 
months was significantly 
different (p=0/01).Therefore 
adding Ca/ Vit. D to the usual 
treatment with clomiphene 
increased the size of follicles, 
especially after the second 
menstrual cycle. 
Intervention period : 
3 months 
Patients randomized 
blocking the two 
groups (n = 22) and 
The control group (22 
cases).The 
intervention group 
received clomiphene 
citrate 50 mg tablets 
with 400 IU of 
vitamin D3 
And 1,000 mg of 
calcium and 50 mg 
clomiphene daily for 
the control group was 
given Plus. Placebo. 
For these patients, 
ultrasound up to three 
cycles, and every 
once in a 13-day 
menstrual cycle was 
conducted to evaluate 
the size of the 
Inclusion: Rotterdam criteria 
Exclusion: Endocrine disease 
for example Cushing's and 
hypothyroidism, 
hyperthyroidism, 
increased blood prolactin 
 
n=44 
infertile 
women. 
20-43 2011 
kermanshah 
4- Robabeh 
Mohammad 
beige(15) 2012 
 Caspian J Intern Med 2019; 10(4):359-369 
Calcium and vit D in polycystic ovary syndrome                                                           363  
dominant follicle and 
if Not positive 
pregnancy test, 
clomiphene dose in 
the second month 
Double treatment 
(100 mg) and in the 
third month treatment 
Three times (150 mg) 
increased 
The presence of Ca/ Vit. D 
caused frequency of regular 
menstrual cycles and 
dominant follicle were 
significantly higher in groups 
1 and 2 than others (P < 0.05) 
but frequency of acne, 
hirsutism and BMI were not 
significant among different 
groups. 
 
Intervention period: 4 
months 
1. Metformin group 
(group1); received 
1500 mg/day 
metformin 500 mg) (n 
= 20.) 
2. Metformin plus 
calcium and Vitamin 
D (group 2); received 
1500 mg/day 
metformin plus 1000 
mg/day calcium 500 
mg) plus 50,000 IU/2 
weeks pearl Vitamin 
D3 (pearl vitamin D3 
50000 IU) (n = 20( . 
 .3. Calcium and 
Vitamin D (group 3); 
received 1000 mg/ 
day calcium plus 
50,000 IU/2 weeks 
pearl Vitamin D3 (n = 
20.) 
Placebo group (group 
4) received two low 
calorie sweetener 
tablets per day (n = 
20.) 
Inclusion: NIH  1990 criteria2 
Exclusion: Cushing 
syndrome, renal failure (Cr 
≥1.5), androgenic ovarian and 
adrenal tumor, primary and 
secondary hyper 
parathyroidism, osteomalasia, 
cancers, gasterectomy, mental 
retardation, anticonvulsive 
drugs use and congenital 
adrenal hyperplasia 
N=80 20-40 2013 
Isfahan 
5- Hatav 
Ghasemi 
Tehrani(16), 
2014 
The mean levels of HOMA in 
group 1 and mean levels of 
QUICKI in group 2 were 
significantly higher than in 
other groups. The percentage 
and the mean diameters of the 
dominant follicles were 
higher in group 2 than in 
group 1. Also, group 2 
showed lower rate of irregular 
menstruation after treatment 
than group 1 but without 
significant difference.  
Therefore calcium and 
vitamin D plus metformin are 
useful in treatment of PCOS 
via modifying insulin and 
causing decreased insulin 
resistance and increased 
insulin sensitivity. 
Intervention period: 
3months 
Women in group 1 
(Metformin only 
group) received 
Glucophage XR 1000 
mg once daily, orally 
and diet. 
-Women in group 2 
(Metformin, vitamin 
D and calcium group) 
received Glucophage 
XR1000 mg once 
daily ,orally as above, 
plus extreme 500 mg 
calcium carbonate + 
200 Iu vitamin D3 
twice daily and diet. 
Gynecological and ultrasound 
examination with general 
criteria of PCOS (hirsutism, 
obesity, etc.). 
N=120 
women 
with 
PCOS 
30/2-
30/5 
2015 
Egypt 
6-Mohamed 
A.Albahi (19) 
2015 
1-According to the Rotterdam criteria the presence of two of the three following characteristics was required for inclusion in the study for PCOS: (1) 
oligomenorrhea/amenorrhea, (2) chemical or clinical findings of hyperandrogenism, and (3) polycystic ovaries on transvaginal Sonography 
2- NIH 1990 criteria1-(Chronic anovulation, 2. Clinical or biochemical evidence of hyper androgenism and 3. Roll out of other causes (thyroid stimulating 
hormone, follicle-stimulating hormone, and prolactin and testosterone measurement). 
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Quality assessment: The quality of the included studies were 
evaluated by Oxford Center for Evidence-Based Medicine 
checklist for RCTs. This tool consists of six general  
questions including the way of patient's assignment, 
similarity, and matching of groups, equality of allocated 
treatment, loss to follow-up and intention-to-treat analysis, 
blindness and effect size which was assessed with three 
answers of yes, no and unclear. Risks of bias assessment are 
shown in figure 2. Two authors independently assessed the 
risk of bias for each study using the criteria outlined in the 
Cochrane Handbook for Systematic Reviews of 
Interventions (fig 3) (14). 
 
Figure 2. Risk of bias summary: Systematic review. Authors’ judgments of each risk of bias item for each included study 
 
Did the 
analysis 
include an 
intention to 
treat analysis? 
Selective 
reporting 
(reporting 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Blinding of 
participants 
and personnel 
(performance 
bias 
Allocation 
concealment 
(Selection 
bias) 
Random 
sequence 
generation 
(Selection 
bias) 
 
+ - - ? ? + - Rashidi 2009  
+ + + + + + + Asemi 2014 
+ + + ? + + - Gharakhani,2015 
+ + ? + + + ? mohammad beigi 
2012 
+ - ? - + + - Ghasemi Tehrani 
2014 
+ ? ? ? + + ? Albahi 2015 
 
Figure 3: Risk of bias graph systematic review. Authors’ judgment of each risk of bias presented as percentage across all 
included studies 
Random sequence generation (Selection bias)    
Allocation concealment (Selection bias)  
Blinding of participants and personnel (performance bias   
Blinding of outcome assessment (detection bias)    
Incomplete outcome data (attrition bias)    
Selective reporting (reporting bias)    
Did the analysis include an intention to treat analysis?    
       Low risk of bias                  High risk of bias                unclear risk of bias 
 
Data synthesis: We interpreted the results using two effect 
sizes, odds ratio (OR) and risk difference (RD). For 
heterogeneity evaluation, Cochrane Q test (p<0.05 as 
statistically significant) and I
2
 index were used. According to 
studies difference, random effects models of analysis were 
used (heterogeneity was not significant, p>0.05; I2=0%). 
The latter was used to assess how much of the variance 
across studies is likely to be real and is not due to sampling 
errors.  
All statistical analyses were done by Comprehensive 
Meta-analysis Version 2 (Biostat, Englewood, NJ, USA). 
Subgroup analysis was performed on metabolic factors. 
 
Results 
Out of 449 relevant published trials, six RCTs met the 
inclusion criteria. All of the six articles were randomized  
controlled trials designed to evaluate the effect of Ca/ Vit. D 
co-supplementation for PCO patients. This study was 
conducted on 435 PCOS women. Five studies defined PCOS 
based on criteria of Rotterdam and one study diagnosed 
PCOS using the National Institutes of Health criterion. Four 
studies were conducted in Iran and one study in Egypt. Four 
of six studies compared women who received metformin 
with or without Ca/ Vit. D. This study included one study 
compared regularity of menses and number of large follicles 
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(15); another compared regularity of menses, dominant 
follicle and hyperandrogenism (16) and one study compared 
metabolic factors and another regularity of menses, follicle 
dominant and glucose metabolism parameters. Two other 
studies, one study compared metabolic parameters between 
different groups receiving ca or vitamin D or both or none of 
them. One study compared distance between menses and 
follicle growth in women receiving clomiphene with or 
without Ca/ Vit. D (15). The summarized characteristics of 
the included studies are shown in table 1. Three of four 
RCTs, reported regularity of menses and follicular 
responses. One of four RCTs did not include in meta-
analysis due to the differences in study design. Figure 3 
shows the forest plots of the meta-analysis on the regularity 
of menses in studies with co-supplementation of Ca/ Vit. D 
with metformin. As shown in figure 3, the effect of adding 
Ca/ Vit. D to metformin on regularity of menses was higher 
than ca/D only (OR2.075 95%; CI 1.421 to5.148], P =002; 
heterogeneity I2=0.000 %; P =0.938). Beigi (2012) used 
Mann Whitney test to assess the differences between the 
group receiving Ca/ Vit. D versus placebo in addition to 
clomiphene (15). No statistically significant difference was 
observed between the average duration of menstruation 
(p=0.7) and the distance between periods (p=0.5) in two 
groups. Figure 4 shows the forest plots of the meta-analysis 
on follicular responses in three studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of adding Ca/ Vit. D to metformin on regularity of menses based on Odds ratio. The horizontal lines denote the 95% CI. 
 
As shown in figure 5, the effect of adding Ca/ Vit. D to 
metformin on follicle response was higher than Ca/ Vit. D 
only but the difference was not significant ((RD, 0.080, 95%; 
CI -0.030 to0.190], P=0.152; heterogeneity I2=0.000 %; 
P=0.152). Beigi (2012) compared two groups with Mann 
Whitney test after 3-month-use of clomiphene citrate (cc) 
combined with calcium and vitamin D or placebo. Changes 
of follicular size was not significant (P=0.1) but the mean of 
follicular size in the first, second and third month following 
intervention was higher in the group who received Ca/ Vit. D 
compared to placebo group (P=0.03, P=0.01, P=0.003) (15). 
Metabolic factors were not included in meta-analysis due to 
differences in study design (17, 18). Co-supplementation 
during 8 weeks with calcium and vitamin D or adding Ca/ 
Vit. D with metformin for 12 week resulted in a significant 
reduction in serum insulin levels (p=0.03, p=0.015) and 
HOMA-IR score (p=0.04, p=0.001) and a significant 
elevation in QUICKI index (p=0.001). Administration of  
 
calcium and vitamin D alone had no significant effect on 
total FPG (fasting plasma glucose) (p=0.08) (18) but along 
with metformin, it had significant reduction (p=0.002, 
p<0.001)) (19, 17). The level of androgenic factors was 
measured by measuring hirsutism or the level of testosterone 
and DHEAS. Hirsutism and the level of testosterone 
decreased significantly after adding Ca/ Vit. D to metformin 
in two different studies (P>0.05, p=0.037) (15, 16); but 
changes in the level of DHEAS was not significant 
(p=0.987) (17). Calcium-vitamin D co-supplementation in 
PCOS women resulted to a significant decrease in serum 
triglycerides (P=0.02) and VLDL-cholesterol levels (P=0.02) 
compared with other groups who had calcium or vitamin D 
alone. However, it had no significant effect on LDL, HDL, 
and non-HDL-cholesterol levels. (18). Gharakhani (2015) 
found that adding Ca/ Vit. D with metformin resulted in 
significant decrease in the levels of cholesterol and LDL 
(P<0.001) (17). 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Rashidi et al 2.600 0.672 10.065 1.384 0.166
Adalbahi et al 3.000 1.227 7.336 2.408 0.016
Ghasemi et al 2.270 0.636 8.106 1.262 0.207
2.705 1.421 5.148 3.029 0.002
0.1 0.2 0.5 1 2 5 10
Favours Metformin Favours Metformin+Ca/D
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Figure 5: Effect of adding Ca/ Vit. D to metformin on follicle response based on risk differences. The horizontal lines 
denote the 95% CI. 
 
Discussion 
The present review supports that serum calcium and 
vitamin D status affect the metabolic and menstrual cycle 
changes and follicle maturation in PCOS patients the 
important sources of heterogeneity, according to meta-
regression findings: the average duration of menstruation 
and the distance between periods were not important sources 
of heterogeneity. The other potential sources of 
heterogeneity in PCOS, regularity of menses and follicular 
responses were assessed.  
Metabolic factors were not included in meta-analysis due 
to differences in study design. Subgroup metabolic factor 
analysis showed that the improvement of hirsutism and the 
levels of testosterone, cholesterol and LDL after adding Ca/ 
vit D. It seems that the effectiveness of clomiphene citrate or 
metformin in combination with calcium and vitamin D in 
improving menstrual regularity and follicular maturation is 
higher than using only metformin or clomiphene. In an 
observational study, prescription of vitamin D with calcium 
therapy resulted in normal menstrual cycles within 2 months 
in nine of thirteen women, from which two women became 
pregnant (20). Firouzabadi (2012) reported that 100 000 IU 
vitamin D for 6 months and 1 000 mg/day calcium co-
administration among PCOS cases resulted in improved 
follicular maturation, regularity of menses, and androgen 
related symptoms especially in women with vitamin D 
deficiency (21). Across studies within Alisa review (2013), 
several studies suggested that calcium metabolism 
dysfunction is associated with impaired oocyte development.  
 
As a result, vitamin D deficiency may alter the 
availability and function of calcium, suggesting that co-
supplementation of vitamin D could correct this imbalance. 
Menstrual irregularity is improved by co-supplementation of 
Ca/ vit. D (22, 23). 
Using Ca/ vit. D with metformin decreased serum 
testosterone and hirsutism. In this systematic review, 
assessing metabolic changes for androgens showed Ca/ vit. 
D in combination with metformin, have positive effect on 
androgenic factors and symptoms. Serum DHEAS, 
testosterone, SHBG and free androgen index (FAI) are used 
as diagnostic markers of hyperandrogenism. In several 
studies, significant reduction in androgenic factor was 
observed compared to baseline values after co- 
supplementation of calcium and vitamin D (21, 23, 24). 
Razavi et al. demonstrated that vitamin D-K-calcium co-
supplementation among vitamin D-deficient women with 
PCOS for 8 weeks resulted in a significant reduction in 
serum-free testosterone and DHEAS, compared to placebo 
(10). Earlier studies have also shown that estrogens and 
androgens directly or indirectly affect vitamin D signaling 
pathways. Vitamin D influences the balance between 
androgens and estrogens, which may have a role in 
pathophysiologic mechanisms of PCOS (8). The prevalence 
of VDD among women with PCOS, BMI, insulin resistance 
parameter affect steroidogenesis. In this systematic review, 
the relationship between VDD and BMI was not seen in all 
of them but Ca/ vit. D co-supplementation had a beneficial 
effect on insulin resistance parameter. 
Study name Statistics for each study Risk difference and 95% CI
Risk Standard Lower Upper 
difference error Variance limit limit Z-Value p-Value
Rashidi et al 0.094 0.096 0.009 -0.094 0.283 0.980 0.327
Adalbahi et al 0.067 0.077 0.006 -0.084 0.218 0.866 0.386
Ghasemi et al 0.100 0.157 0.025 -0.207 0.407 0.639 0.523
0.080 0.056 0.003 -0.030 0.190 1.432 0.152
-0.50 -0.25 0.00 0.25 0.50
Favours Metformin Favours Metformin+Ca/D
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Ca/ vit. D co- supplementation had also a beneficial 
effect on glucose metabolism in this review. In the study of 
firouzabadi (2012) in Yazd, Iran positive effect was seen on 
insulin resistance after the six-month treatment with 
metformin and Ca/ vit. D, especially in women with vitamin 
D deficiency (21). Bonakdaran (2012) showed that 
prescribing calcitriol for three months has not significant 
relationship between vitamin D level and fasting blood 
sugar, blood glucose two hours after 75 gr glucose and 
insulin level and HOMA-IR after calcitriol (9). Selimoglu et 
al. (2010) in contrast, showed improvement in HOMA 
indices within 3 weeks of a single oral mega dose of 300,000 
IU D3 in a pilot study on 11 women with PCOS, (25). In an 
exhaustive medical literature search, which was conducted 
by Galusha (2013), multiple studies suggested a weak 
improvement in menstruation regularity, fertility, BMI, 
insulin resistance, glucose metabolism and 
hyperandrogenism following CA/Prescription(23). A meta-
analysis conducted by Chunla He (2015) revealed an inverse 
correlation of serum vitamin D concentrations with HOMA-
IR, triglycerides, but positive correlation with HDL-
cholesterol ratio and QUICKI (26). 
 In another study, no correlation was seen between 
vitamin D deficiency and its severity with complications of 
PCOs including obesity and insulin resistance in high school 
girls who had hypovitaminos D (27). Physiologic functions 
of active vitamin D affect glucose and insulin metabolism. 
Factors that affect glucose metabolism included follow up 
duration, BMI before and after treatment, VDD, duration for 
treatment and diet which has been reviewed in studies with 
different methodologies. 
This review showed that calcium and vitamin D had 
beneficial effect on some lipid parameters, such as HDL, TG 
and VLDL. Chunla (2015) and some authors reported that 
supplementation of vitamin D does not significantly improve 
metabolic and endocrine parameters (except triglycerides 
and fasting insulin) (25). Some studies have shown that 
magnesium-zinc-calcium-vitamin D co supplementation for 
12 weeks in PCOS women was associated with a significant 
reduction in serum TG, VLDL, total-cholesterol 
concentrations, total-/HDL-cholesterol ratio, but did not 
influence other lipid parameters (28). Other studies showed 
that co-administration of Ca/ vit. D significantly improve 
lipid profile (29, 30, 31). Al-Hakeim (2009) found that the 
level of serum Lipids is not correlated with the serum 
calcium (32). Vitamin D regulates adiposity activity which 
possibly is related to its potential benefit with respect to 
insulin sensitivity. The effect of vitamin D on serum 
triglycerides concentrations is still not known (18, 33). In 
most of reviewed studies diet, parathyroid hormones and 
vitamin D levels have not been evaluated. 
The important limitations in the current study are few 
studies focused on calcium and vitamin D supplementation 
conducted with randomized designs. On the other hand, 
dosage of calcium and vitamin D supplementation and 
patients’ baseline serum vitamin D levels varied from study 
to study, thereby; there is uncertainty that all patients were 
administered with sufficient amount of calcium and vitamin 
D supplement. Included studies varied in the definitions of 
PCOS, which may have affected the assessment of the role 
of calcium and vitamin D on metabolic parameters in PCOS. 
There was small sample size, inadequate treatment allocation 
and insufficient duration of the intervention.  
Deficiency of vitamin D was uncertain except in only one 
study that may affect the effectiveness of the treatment. Also 
publication bias could be a possible threat for the validity of the 
results, therefore the findings should be interpreted with 
cautiousness (34, 35). Further studies with longer duration of 
the intervention, and larger sample size are required to 
confirm our findings. 
The main finding of this study which is calcium and 
vitamin D supplementation may improve metabolic 
parameters and menstrual disturbances in PCOS cases. 
However, it cannot be ruled out that calcium and vitamin D 
supplementation may be a minor pathway towards PCOS, 
given the small intervention studies and the variability of 
their results. Thus, long-term, and multiple randomized 
clinical trials are needed to be conducted to determine 
whether vitamin D and calcium supplementation affect co -
morbidities with PCOS and to demonstrate the benefits of 
calcium and vitamin D supplementation in treatment of 
women with PCOS. 
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